Mesonephric adenocarcinoma treated with paclitaxel-carboplatin adjuvant chemotherapy: a case report

The authors describe a case of a mesonephric adenocarcinoma of the meso-ovarium and meso-salpinx in a 52-year-old woman. The patient underwent total laparoscopic hysterectomy, bilateral salpingo-oophorectomy, followed by adjuvant chemotherapy with paclitaxel and carboplatin for six cycles with three-week intervals in between. The patient remained free of disease for 18 months with good general conditions. They also reviewed the clinical, pathological, and immunohistochemical characteristics of 42 published case reports of mesonephric adenocarcinoma. The most common presentation of the disease was vaginal bleeding, followed by low abdominal pain. Among the 42 cases reviewed, only three patients were given the correct diagnosis preoperatively. A significant portion of them showed positive immunoreactivity for CD10, vimentin, and calretinin. The authors also found that AE1/AE3, CK7, EMA, CD10, and vimentin are typically positive while ER, PR, and CEA are usually negative. Among the cases reviewed, adjuvant chemotherapy was performed in 11 (26.2%) patients while adjuvant radiotherapy was performed in 16 (38.1%) patients. A number of chemotherapeutic regimens have been used but responses to such regimens are still inconclusive. Although further experiences are needed, surgical removal of the mass followed by paclitaxel and carboplatin adjuvant chemotherapy may be considered as a viable option for treatment.

Mesonephric adenocarcinoma; Hysterectomy; Chemotherapy; Paclitaxel; Carboplatin

[1] Bague S., Rodriguez I.M., Prat J.: “Malignant mesonephric tumors of the female genital tract: a clinicopathologic study of 9 cases”. Am. J. Surg. Pathol., 2004, 28, 601.

[2] McCluggage W.G., Oliva E., Herrington C.S., McBride H., Young R.H.: “CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma”. Histopathology, 2003, 43, 144.

[3] Clement P.B., Young R.H., Keh P., Ostor A.G., Scully R.E.: “Malignant mesonephric neoplasms of the uterine cervix. A report of eight cases, including four with a malignant spindle cell component”. Am. J. Surg. Pathol., 1995, 19, 1158.

[4] Lang G., Dallenbach-Hellweg G.: “The histogenetic origin of cervical mesonephric hyperplasia and mesonephric adenocarcinoma of the uterine cervix studied with immunohistochemical methods”. Int. J. Gynecol. Pathol., 1990, 9, 145.

[5] Silver S.A., Devouassoux-Shisheboran M., Mezzetti T.P., Tavassoli F.A.: “Mesonephric adenocarcinomas of the uterine cervix: a study of 11 cases with immunohistochemical findings”. Am. J. Surg. Pathol., 2001, 25, 379.

[6] Valente P.T., Susin M.: “Cervical adenocarcinoma arising in florid mesonephric hyperplasia: report of a case with immunocytochemical studies”. Gynecol. Oncol., 1987, 27, 58.

[7] Montagut C., Marmol M., Rey V., Ordi J., Pahissa J., Rovirosa A., et al.: “Activity of chemotherapy with carboplatin plus paclitaxel in a recurrent mesonephric adenocarcinoma of the uterine corpus”. Gynecol. Oncol., 2003, 90, 458.

[8] Buntine D.W.: “Adenocarcinoma of the uterine cervix of probable Wolffian origin”. Pathology, 1979, 11, 713.